Exelixis: huling pagsusuri ng OS ng STELLAR-303 (non-liver mets) sa kalagitnaan ng 2026

Nakasaad sa dokumento na ang huling pagsusuri ng STELLAR-303 sa pangalawang dual primary endpoint (OS sa mga pasyenteng walang liver metastases) ay inaasahan sa kalagitnaan ng 2026. Ito ang susunod na regulatory readout para sa NDA na kasalukuyang nasa ilalim ng FDA review para sa zanzalintinib + atezolizumab sa mga pasyenteng may previously treated CRC.

Mahahalagang fact

Na-file: Ene 12, 2026, 09:22 PM
Kaganapan: Naitakda ang petsa ng PDUFA
Direksyon: Neutral
Kumpanya: EXELExelixis
Asset: zanzalintinib
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

EX-99.1 2 exel20260111exhibit991.htm EX-99.1 Document Exhibit 99.1 Investor Contacts: Andrew Peters SVP, Strategy and Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 hal@torchcommunications.com Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 – Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion – – Presentation and webcast at J.P. Morgan 2026 Healthcare Conference to

SEC 8-K